No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt by Riggio, Oliviero et al.
ORIGINAL ARTICLE
No effect of albumin infusion on the prevention of hepatic
encephalopathy after transjugular intrahepatic
portosystemic shunt
Oliviero Riggio1,2 & Silvia Nardelli1 & Chiara Pasquale1 & Ilaria Pentassuglio1 &
Stefania Gioia1 & Eugenia Onori1 & Camilla Frieri1 & Filippo Maria Salvatori1 &
Manuela Merli1
Received: 16 March 2015 /Accepted: 16 July 2015 /Published online: 20 August 2015
# European Union 2015
Abstract Hepatic encephalopathy (HE) is a major problem in
patients submitted to TIPS. Previous studies identified low
albumin as a factor associated to post-TIPS HE. In cirrhotics
with diuretic-induced HE and hypovolemia, albumin infusion
reduced plasma ammonia and improved HE. Our aim was to
evaluate if the incidence of overt HE (grade II or more accord-
ing to WH) and the modifications of venous blood ammonia
and psychometric tests during the first month after TIPS can
be prevented by albumin infusion. Twenty-three patients con-
secutively submitted to TIPS were enrolled and treated with
1 g/Kg BWof albumin for the first 2 days after TIPS followed
by 0,5 g/Kg BW at day 4th and 7th and then once a week for
3 weeks. Forty-five patients included in a previous RCT
(Riggio et al. 2010) followed with the same protocol and sub-
mitted to no pharmacological treatment for the prevention of HE,
were used as historical controls. No differences in the incidence
of overt HE were observed between the group of patients treated
with albumin and historical controls during the first month (34 vs
31 %) or during the follow-up (39 vs 48 %). Two patients in the
albumin group and three in historical controls needed the reduc-
tion of the stent diameter for persistent HE. Venous blood am-
monia levels and psychometric tests were also similarlymodified
in the two groups. Survival was also similar. Albumin infusion
has not a role in the prevention of post-TIPS HE.
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Abbreviations
TIPS Transjugular intrahepatic portosystemic shunt
DST Digit-symbol test
TMT-A Trail-making test A
TMT-B Trail-making test B
Introduction
Transjugular intrahepatic portosystemic shunt (TIPS) is
currently used for the treatment of the complications of
portal hypertension (Cabrera et al. 1996; Sanjal et al.
1996; Rossle et al. 1997, 2000; Merli et al. 1998; Lebrec
et al. 1996; Gines et al. 2002; Sanyal et al. 2003; Salerno
et al. 2004). This procedure, however, involves two main
drawbacks: the occurrence of shunt dysfunction (Cabrera
et al. 1996; Merli et al. 1998; Lind et al. 1994; LaBerge
et al. 1995; Nazarian et al. 1994; Latimer et al. 1998) and
of hepatic encephalopathy (HE) which is very frequent
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after a TIPS (Sanjal et al. 1994; Jalan et al. 1995;
Somberg et al. 1995; Riggio et al. 1996; Zuckerman
et al. 1997; Nolte et al. 1998). Moreover, post TIPS HE
refractory to standard treatments may occur in about 8 %
of patients (Riggio et al. 2008). Unfortunately, until now,
no attempt aimed at reducing the incidence of post-TIPS
HE has been successful. A RCT failed to show an effect
of the administration of non-absorbable disaccharides or
antibiotics on the incidence of HE during the first month
after TIPS procedure (Riggio et al. 2005). Moreover, the
use of stents with lower diameter (8 versus 10 mm) failed
to reduce the incidence of post TIPS HE and resulted less
efficient in controlling the complications of portal hyper-
tension (Riggio et al. 2010).
A previous study (Riggio et al. 2008) on the inci-
dence of HE in patients submitted to TIPS with PTFE
covered stents identified older age, high creatinine
levels, low serum sodium and albumin levels as inde-
pendent factors associated to post TIPS HE, suggesting
that hypovolemia may be involved in the pathogenesis
of this complication and that the correction of hypovo-
lemia might be useful in its prevention. The effect of
albumin in patients submitted to TIPS has never been
tested, but in a small clinical trial (Rajiv and Dharmesh
2004), albumin infusion was able to ameliorate HE and
to increase urinary ammonia excretion on cirrhotic pa-
tients with diuretic-induced HE. In that study, albumin
was more efficient then other plasma expander suggest-
ing that albumin, in addition to its plasma expander
capacity may have other potential effects. Albumin is
able to bind different molecules (fatty acids, bilirubin,
bile salts, amino acids and nitric oxide), to influence the
redox balance by reducing oxidative stress and to re-
duce brain swelling in a model of ischemic stroke in
experimental animals (Belayev et al. 2001). Based on
the above considerations, albumin infusion was tested
for the treatment of overt HE in cirrhotic patients in a
recent RCT (Simón-Talero et al. 2013). Moreover, TIPS
placement induces a complex modification of systemic
hemodynamic resulting in increased cardiac output, de-
creased peripheral vascular resistance and increase of
cerebral blood flow (Kavitt et al. 2008). This increment
may amplify the availably of ammonia to the brain and
facilitate the astrocytes swelling, a condition which may
be facilitated by a pre-existing hyponatremia. Thus, a
treatment to reduce brain swelling may be beneficial.
The above considerations encouraged us in testing the ef-
ficacy of albumin infusion in the prevention of HE after TIPS
in a pilot study aimed at eventually supporting the proposal of
a randomized controlled trial. We compared the incidence of
post TIPS HE observed in this pilot study to that observed in a
previous randomized control trial designed for the prevention
of post TIPS HE (Riggio et al. 2010).
Patients and methods
All consecutive cirrhotics admitted to our Gastroenterology
Unit to be submitted to TIPS were enrolled. Exclusion criteria
corresponded to the contraindications to TIPS used in our
centre: past or present history of recurrent HE, serious cardiac
or pulmonary dysfunction, diagnosis of hepatocellular carci-
noma, sepsis.
The purpose of the study, the enrolment, the follow-up and
the details of TIPS operation were explained to the patients
and a written informed consent was obtained. The study pro-
tocol conformed to the ethical guidelines of the 1975 Decla-
ration of Helsinki and was approved by the Ethical and the
Research Committees of the BSapienza^ University of Rome.
The study was registered in Clinicaltrials.gov with the number
NCT01559519.
All patients were hospitalized before TIPS placement. At
enrolment the patients’medical histories were collected; phys-
ical examinations, calculations of Child-Pugh’s and MELD
scores, doppler ultrasonography and upper gastrointestinal en-
doscopy were carried out. TIPS procedures were performed
by the same radiology team as previously described. (Merli
et al. 1998; Sampietro et al. 1998; Angeloni et al. 2004; Rossi
et al. 2004). Endoscopy was repeated 1 week after TIPS. The
patients remained in hospital for at least 7 days after TIPS
placement and were successively seen weekly during the first
month. Ultrasonography was repeated weekly to exclude
shunt dysfunction. Shunt patency was assessed with color-
Doppler, measurement of the mean flow velocity and direc-
tion within the shunt at three sites (proximal, medial and distal
portion), in the portal vein and in intrahepatic portal branches.
The diameters of the stent, the portal vein and the spleen were
also measured. All the subjects were evaluated and followed-
up by the same medical team by a prospective protocol diag-
nostic work-up and a surveillance strategywhichwas identical
to that used in a previously published RCTwhich provided the
historical controls (Rajiv and Dharmesh 2004).
Patients were treated with albumin infusion according to
the following scheme: 1 g/Kg body weight for the first 2 days
after TIPS followed by 0,5 g/Kg body weight at day 4 and
then 0,5 g/Kg body weight once a week for the remaining
3 weeks.
The albumin (Human Albumin 20 % solution) used for the
study was kindly supported by GORE srl which is the produc-
er of the PTFE covered stents used in our university hospital
(Viatorr®,W.L. Gore & Associates, Inc., Flagstaff, AZ, USA).
GORE was not involved in the conception, protocol, analysis
of the results and discussion of the study.
Evaluation of HE
The day before the procedure, a basal evaluation of HE in-
cluding examination and grading of the patients’ mental state,
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asterixis, and psychometric performance [TMT-A and TMT-
B; Digit Symbol, (DS)] as well as their venous blood ammo-
nia determination were carried out. The evaluation of the de-
gree of HE was based on the alteration of the patient’s mental
state using modifications of the West Haven Criteria (Conn
et al. 1977). Blood samples from a peripheral vein were col-
lected into iced tubes for ammonia determination, performed
immediately after using the Ammonia Checker II (Menarini,
Florence, Italy), as previously described (Nicolao et al. 2003).
This workout (evaluation of mental status, psychometric per-
formance and venous blood ammonia determination) was re-
peated at weekly intervals during the first month after the
TIPS procedure. TMT-A, TMT-B, and DS results were
expressed as Z-score, adjusted for the main confounders
(age and education) according to Amodio et al. (Amodio
et al. 2002). Both the patients and their families were
instructed about the importance of an immediate contact with
the medical staff should any alteration in the mental state
occur in between the scheduled visits. In particular, the family
was instructed to refer to the occurrence of lethargy, apathy,
obvious personality change, inappropriate behaviour, or dis-
orientation for time and place (corresponding to a grade-II
alteration of the patients’ mental state). In this case, the HE
evaluation, including the psychometric performance, was re-
peated to confirm and stage the degree of HE. None of the
patients received any pharmacological treatment to prevent
the occurrence of HE, in particular lactulose or rifaximin were
avoided. Once developed, HE was treated with oral adminis-
tration of non-absorbable disaccharides or non-absorbable an-
tibiotics. All potential HE precipitating events were treated.
End-points
The primary end-point of the study was the incidence of overt
HE (grade II or higher grades) in the first month after TIPS
placement. All the other episodes of HE occurring during the
follow-up were also recorded. Other outcomes of interest
were: the modification of blood ammonia and of the psycho-
metric performance 1 month after TIPS; the occurrence of
refractory HE defined as recurrent HE (at least three episodes
of non-precipitant-induced HE requiring hospitalization in the
last 3 months despite continuous treatment with lactulose) or
persistent HE (presence of continuously detectable altered
mental state with further episodic deterioration despite protein
restriction and treatment with lactulose) and survival.
Statistical analysis
Results are expressed as Bmean±SD^. Comparisons to histor-
ical data from a previously published RCT (Riggio et al. 2010)
were included, based on methodology and recommendations
from regulatory guidance and published literature (Gehan
1984; Pocock 1976; Food and Drug Administration Center
for Drug Evaluation and Research (CDER) Center for Bio-
logics Evaluation and Research (CBER) 2001). In this histor-
ical RCT, enrolment criteria, patients ‘evaluation and follow-
up as well as clinical end-points were similar to those adopted
in the present study. Moreover, the two studies were supported
by the same organization and investigators.
Comparisons among the groups were performed for quan-
titative data by the Student’s t-test. The chi-squared test was
used to determine the differences in proportions. The inci-
dence of HE as well as of the other outcomes of the study,
including mortality was calculated by the Kaplan–Meier
method (Kaplan and Meier 1958) and compared by the log-
rank test. Follow-up was measured in months from the date of
successful TIPS procedure until death, liver transplantation, or
the most recent clinical examination. Patients were considered
lost to follow-up if they did not show up at two consecutive 6-
month clinical examinations. The SPSS program was used for
all computations.
Sample size calculation
On a previous study on the pharmacological prophylaxis of
post-TIPS HE (Riggio et al. 2005) the incidence of HE during
the first month after TIPS was 33 %, (95 % CI 22–45 %). It is
thus estimated that a group of 20 patients would be required to
observe a reduction of this rate to about 10 %.
Results
The demographic, clinical and biochemical characteristics of
the patients are reported in Table 1. For comparison, the same
parameters observed in the historical controls are also report-
ed. There were no significant differences between the two
groups in clinical and laboratory data at the time of TIPS
placement. Both groups were comparable for age, gender,
aetiology and severity of liver disease including Child-Pugh
andMELD scores. They also had a similar history of previous
ascites andHE and did not differ concerning the size of varices
and the indications for TIPS. TIPSs were successfully im-
planted in all patients. After TIPS placement, the porto-
systemic pressure gradient significantly decreased in both
groups (from 18.6±5.2 to 5.4±3.6 mmHg in the albumin
group and from 22.3±6.7 to 7.1±3.9 mmHg in the historical
control group; p<0.001 in both groups). During the first
month after TIPS, HE occurred in 8 of the 23 patients
(34 %) in the albumin group. HE occurred spontaneously in
three patients, while infection was the precipitating event in
the remaining five patients. The eight patients with overt HE
during the first month of follow up were older (64±3 vs 54±
11 years; p=0.01) and with higher TMT-B (147±45 vs 98±
41 s.; p=0.04) than the patients without overt HE. During the
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first month after TIPS, overt HE occurred in 14 of the 45
patients (31 %) in the control group.
Three patients in the historical control group and two pa-
tients in the study group were lost to follow-up. These patients
were included in the analysis and censored at the time of the
last visit. The cumulative incidence of HE during the follow
up was not statistically different in the patients treated with
albumin and in the historical controls (Fig. 1). Two of the 23
patients treated with albumin suffered of a refractory HE
(8 %), which did not respond to the medical therapy. In one
patient chronic HE started within the first month after TIPS. In
these two patients the cognitive impairment improved after the
reduction of the calibre of the stent. The porto-systemic pres-
sure gradient before the diameter reduction was 11 and
9.8 mmHg, respectively. Three of the 45 patients among the
historical controls experienced refractory HE (7 %). At base-
line there were no significant differences between the two
groups in the venous ammonia levels and in TMT-A and
TMT-B. DS test was slightly better in the control group
(Table 1). After TIPS placement, venous ammonia levels
increased significantly in both groups. The psychometric per-
formance was unmodified after TIPS (Table 2).
Five patients in albumin group (22 %) died during the
follow-up. Deaths were due to an accident in one patient, to
a stroke in another one and to liver failure in the other patients.
Eight patients in historical control group (18 %) died during
follow up (Fig. 2).
Discussion
The present study failed to show that the volume espansion
induced by the infusion of albumin was able to reduce the
incidence of overt HE after TIPS. In fact, compared to the
hystorical controls, the cumulative incidence of overt HE
Fig. 1 Cumulative incidence of Hepatic Encephalopathy during the
follow-up in the patients treated with albumin and in the historical
controls
Table 1 Demographic and clinical characteristics of the patients
included in the study and the historical controls (Riggio O. et al. J
Hepatol. 2010)
Albumin
(n=23)
Historical
Controls (n=45)
P Value
Sex (M/F) 17/6 28/17 Ns
Age (yrs.) 57.7±10 55.2±10.7 Ns
Etiology (virus/
alcohol/other)
9/8/6 18/18/9 Ns
MELD 11.5±3.3 10.4±4.2 Ns
Child Pugh class
(A/B/C)
7/14/2 10/25/10 Ns
TIPS indication
(bleeding/
refractory ascites)
13/10 21/24 Ns
Previous HE n.
of pts. (%)
0 (0 %) 9 (20 %) 0.02
Bilirubin (mg/dl) 1.5±1.4 1.7±1.4 Ns
Albumin (g/dl) 3.3±0.6 3.4±0.5 Ns
Sodium (mEq/L) 136±5 137.4±4.9 Ns
Portosystemic Pressure
Gradient (mmHg)
pre-TIPS
18.6±5 22.3±6.7 0.04
Portosystemic Pressure
Gradient (mmHg)
after TIPS
5.4±3.6 7.1±3.6 Ns
Venous ammonia
level (μg/dl)
41±15 48±31 Ns
TMT-A (sec) 58±25 60±40 Ns
TMT-B (sec) 116±55 110±62 Ns
DS (n) 23±9 31±13 0.01
Mean follow-up (months) 6.6±4.8 8.6±9 Ns
Table 2 Comparison of psychometric tests and venous ammonia levels
before and 1 month after TIPS placement
Albumin group (17 pts)
Pre-TIPS After TIPS P Value
TMT-A (sec) 59.1±28.6 64.6±35.6 Ns
TMT-B (sec) 116.4±62.6 138.6±95.2 Ns
DS (n°) 24.5±9.8 21.8±10.9 Ns
Venous ammonia (μg/dl) 40.7±12.2 89±32 0.001
Historical controls (31 pts)
Pre-TIPS After TIPS P Value
TMT-A (sec) 55.6±38.7 51.2±34.5 Ns
TMT-B (sec) 99.2±48.7 117.1±79.6 Ns
DS (n°) 33.7±12 34.7±14.6 Ns
Venous ammonia (μg/dl) 47.6±36.6 89.7±46.6 0.001
Paired t test
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was similar both during the first month and during the whole
follow up. Moreover, the number of patients with persistent
HE refractory to treatment and necessitating the reduction of
the stent diameter was also similar as well as the modifications
of venous ammonia and psycometric tests 1 month after TIPS.
Although, based on the result of a pilot study with hystorical
controls and not of a randomised controlled trial, we conclude
that albumin infusion has no role in the prevention of post-
TIPS HE.
The choice of carring on a pilot study instead of a
RCT was based on different considerations. First, the
possible role of albumin in the prevention of HE after
TIPS was postulated more on the basis of a statistical
association than on pathophysiological considerations.
Hypoalbuminemia was found to be a risk factor for
HE after TIPS in two studies [16; 20]. In the latter, in
common with albumin, also high creatinine levels and
low serum sodium concentration were independently as-
sociated to post TIPS HE, suggesting a role for hypo-
volemia in the pathogenesis of this complication. Hypo-
volemia may increase plasma ammonia levels by reduc-
ing urinary ammonia excretion or by inducing circulato-
ry abnormalities including changes in cerebral blood
flow and metabolism (Iversen et al. 2009). Actually,
volume expansion induced by saline infusion resulted
in a reduction in plasma ammonia concentrations and
an increase in urinary ammonia excretion in 16 well
compensated cirrhotic patients without HE (Jalan and
Kapoor 2003). Moreover, albumin infusion was able to
ameliorate HE and to increase urinary ammonia excre-
tion in eight cirrhotic patients with diuretic-induced HE.
Another possible role of albumin in HE treatment de-
rives from its scavenger action.
On the other hand, we are confident that our conclusion
based on the comparison between the study group treated with
albumin and the hystorical controls are quite reliable. In fact,
our hystorical control group included patients enrolled in a
RCT (Riggio et al. 2010) previously carried on with the same
inclusion criteria of this study. In particular, both the patients
included in the study group and the historical controls were
enrolled, operated on and prospectively followed-up by the
same investigators by using the same methodology to estab-
lish the incidence of HE as well as the modification cognitive
fuction and plasma ammonia after TIPS. Thus the present
study is based on methodology and recommendations from
regulatory guidance and published literature for the use of
hystorical controls (Gehan 1984; Pocock 1976; Food and
Drug Administration Center for Drug Evaluation and Re-
search (CDER) Center for Biologics Evaluation and Research
(CBER) 2001).
The possibility that our negative results could depend on
the administration of insufficient amount of albumin, may not
be completely ruled out. We used 1 g/Kg body weight for the
first 2 days after TIPS followed by 0,5 g/Kg body weight at
day 4 and then by 0,5 g/Kg body weight once a week for
3 weeks to obtain a plasma expansion immediately after TIPS
and for the following 4 weeks. This amount was chosen be-
cause in cirrhotic patients, the dose used to obtain a significant
blood volume expansion was 1,5 and 1,0 g/kg BW at day 1
and 3 respectively in patients affected by spontaneous bacte-
rial peritonitis (Sort et al. 1999) and 1,0 g/kg BW for 2 days in
patients with suspected hepato-renal syndrome (Salerno et al.
2007). In experimental animals with ischemic stroke, the in-
fusion of 0.7–1.25 g/kg BW of albumin was able to obtain a
reduction in brain swelling. Finally, the maintenance dose of
0.5 g of albumin per Kg BW, every week for further 3 weeks
was based on practical considerations.
Another point to be underlined derives from the observa-
tion that an infection was identified and considered as the
precipitating event in 5 out of the 8 patients who experienced
HE during the first month after TIPS. Thus, only three patients
had a spontaneous HE which may directly linked to the open-
ing of the porto-systemic shunt. This was not the experience in
our historical controls, in whom post TIPS HE was spontane-
ous in all cases. Thus, on this point, the methodology used
(pilot study and not RCT) may be relevant. Finally, in a re-
cently published RCT albumin infusion failed to improve the
resolution of HE during hospitalization (Simón-Talero et al.
2013) suggesting that albumin does not have a major impact
on HE in cirrhotics that develop an episode of HE.
Our results are in keeping with this observation and suggest
that albumin has no impact prevention of HE after TIPS.
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